Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1][5] Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 16, 2025 [3] - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding the company's financial status and operational funding [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]
ZBIO FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO